Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

43.76 -0.40 (-0.91%)
Official Closing Price Updated: 7:00 PM EDT, Sep 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,962,303
Open 44.17
Bid (Size) 43.75 (3)
Ask (Size) 44.03 (10)
Prev. Close 44.16
Today's Range 43.73 - 44.60
52wk Range 40.94 - 61.71
Shares Outstanding 5,606,688,356
Dividend Yield 3.56%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
4 Blue-Chip Stocks to Sell in October
Blue-chip stocks to sell as they seem to be trading at stretched valuations considering the economic outlook. These stocks are worth accumulating after a correction of 10% to 20%. 
Via InvestorPlace
What Are Whales Doing With Pfizer
A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 11 strange trades. 
Via Benzinga

Performance

YTD
-22.75%
-22.75%
1 Month
-4.25%
-4.25%
3 Month
-15.26%
-15.26%
6 Month
-14.10%
-14.10%
1 Year
+3.16%
+3.16%

More News

Read More
Biohaven's ALS Drug Fails To Meet Study Endpoint, Second Therapy To Fail Trials In Recent Months
Via Benzinga
Merck Inks Supply Deal With Sinopharm To Commercialize COVID-19 Pills In China
Via Benzinga
CDC and FDA Misinformation – Retroactive Editing, Erroneous Spontaneous Abortion Rate Calculation, Obfuscation by NEJM
Via Newsworthy
Exposures COVID-19 Product Safety
Pfizer To Supply 6M COVID-19 Therapy Courses To Low Income Countries
Via Benzinga
The Road to Health never ends
Via eTrendy Stock
Exposures COVID-19
As Moderna Grapples With Supply Shortage, FDA Gives Nod To Additional Lots of COVID-19 Booster
Via Benzinga
7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic’s Over’
Via InvestorPlace
iPhone 14 Popular In China?, Netflix May Lose Comics, Elon Musk's Starlink Slows, Byron Allen Faces $10B Lawsuit And More Top Financial Media Stories Monday, Sept. 26
Via Benzinga
Pfizer/BioNTech Seek FDA Emergency Nod For Updated COVID-19 Shot For Kids Under 11 Years
Via Benzinga
Pfizer CEO Contracts COVID-19 Infection For Second Time
Via Benzinga
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Kids, But Scrambles Supply Challenges
Via Benzinga
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
From Pfizer Inc.
Via Business Wire
Switzerland To Dispose 10M Expired COVID-19 Vaccine Doses From Moderna
Via Benzinga
Pfizer Resumes Dosing In Phase 3 Hemophilia Gene Therapy Trial Six Months After FDA Lifts Clinical Hold
Via Benzinga
The Worst Thing That Can Happen to the Human Species, is Happening – Dr. Naomi Wolf is Available for Interview
Via Newsworthy
Topics Lawsuit
Exposures COVID-19 Financial Legal
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Here Are Novavax's U.S. Vaccination Numbers — And They're Bleak
Via Investor's Business Daily
The 'Transformative' Eli Lilly Drug That Could Top $25 Billion In Annual Sales
Via Investor's Business Daily
Why Is Novavax (NVAX) Stock Falling Today?
Via InvestorPlace
Pfizer Declares Fourth-Quarter 2022 Dividend
From Pfizer Inc.
Via Business Wire
Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries
From Pfizer Inc.
Via Business Wire
Novavax Remains a Risk-On Stock in a Risk-Off Market
Via MarketBeat
Topics Earnings
Exposures Financial
This Is What Whales Are Betting On Pfizer
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.